---
title: "Australia's CSL surges 18% on earnings beat, upbeat plasma business forecast"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296164347.md"
description: "Australian biotechnology giant CSL saw its shares surge 18%, marking its best intraday session since 2001, after reporting better-than-expected annual underlying earnings. The company forecast growth for 2027 driven by its core plasma division, boosting investor confidence in the world's top flu vaccine maker."
datetime: "2026-08-18T01:48:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296164347.md)
  - [en](https://longbridge.com/en/news/296164347.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296164347.md)
generator: "portal-rs"
---

# Australia's CSL surges 18% on earnings beat, upbeat plasma business forecast

By Sherin Sunny and Nikita Maria Jino Aug 18 (Reuters) - CSL reported better-than-expected annual underlying earnings on Tuesday and forecast growth in 2027 on the back of its core plasma division, sending the Australian biotechnology giant's shares up 18% in their best intraday session since 2001. CSL, among the world's top flu vaccine makers, posted underlying net profit after tax attributable

### Related Stocks

- [CSL.AU](https://longbridge.com/en/quote/CSL.AU.md)
- [CSLLY.US](https://longbridge.com/en/quote/CSLLY.US.md)

## Related News & Research

- [Ord Minnett Remains a Hold on CSL (CMXHF)](https://longbridge.com/en/news/297715214.md)
- [CSL Enters Agreements With U.S. Government To Lower Drug Prices](https://longbridge.com/en/news/297553911.md)
- [CSL signs U.S. government agreements to lower drug prices for Medicaid](https://longbridge.com/en/news/297567342.md)
- [Rare-Disease Drug Tavneos Faces UK Withdrawal](https://longbridge.com/en/news/297819339.md)
- [NAB chief economist sees 7% peak-to-trough drop in Australian capital city dwelling prices](https://longbridge.com/en/news/297851268.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**